Citations

Clear

3942 citation(s) found for "To, Van".

Macrophage Density Predicts Facial Nerve Outcome and Tumor Growth after Subtotal Resection of Vestibular Schwannoma
Graffeo, Christopher S. , Perry, Avital , Raghunathan, Aditya , Kroneman, Trynda, Jentoft, Mark E. , Driscoll, Colin L. W., Neff, Brian, Carlson, Matthew L. , Jacob, Jeffrey T. , Link, Michael J. , Kroneman, Trynda N, Jentoft, Mark, Driscoll, Colin L., Raghunathan, Aditya , Neff, Brian A., Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2018 | Volume: 79 | Issue: 05 | Pages: 482-488

10.1055/s-0038-1627474 | PMID 30210976 Get It

Introduction Vestibular schwannoma (VS) behavior following subtotal resection (STR) is highly variable. Overall progression rates have been reported as high as 44%, and optimal treatment is controversial. Correspondingly, identification of a reliable clinical or pathologic marker associated with progression after STR would help guide decision-making. Methods A prospectively maintained institutional VS registry from 1999 to 2014 was retrospectively reviewed for sporadic VS patients who underwent primary STR without preceding stereotactic radiosurgery (SRS) by a single neurosurgery-neurotology team. Primary endpoints included tumor progression and postoperative facial nerve function. Pathologic specimens were stained for Ki67, CD68, S100, and SOX10 and were quantitated by digital imaging analysis. Macrophage density was defined as the ratio of CD68+ macrophages to S100+ macrophages and Schwannian tumor cells. Clinical outcomes were correlated with pathologic markers. Results Forty-six patients met the study inclusion criteria. Thirteen (28%) progressed during a mean 57 months of follow-up (range 15–149). Favorable postoperative facial nerve function (House–Brackmann I–II) was achieved in 37 (80%). CD68+ cells were present at significantly higher concentrations in tumors that progressed (p = 0.03). Higher macrophage density was significantly associated with both tumor progression (p = 0.02) and unfavorable facial nerve function (p = 0.02). Ki67 percent positivity was not significantly associated with either primary endpoint (p = 0.83; p = 0.58). Conclusions Macrophage density may provide an important marker for individuals at the highest risk for progression of VS after STR, potentially prompting closer surveillance or consideration for upfront SRS following STR. This finding supports preceding conclusions that an intratumoral macrophage-predominant inflammatory response may be a marker for tumor growth and a potential therapeutic target.
Proposed consensus definitions for new‐onset refractory status epilepticus (NORSE), febrile infection‐related epilepsy syndrome (FIRES), and related conditions
Hirsch, Lawrence J. , Gaspard, Nicolas , Baalen, Andreas van , Nabbout, Rima , Demeret, Sophie , Loddenkemper, Tobias , Navarro, Vincent , Specchio, Nicola , Lagae, Lieven , Rossetti, Andrea O. , Hocker, Sara E. , Gilmore, Emily J. , Khosravani, Houman , Rosenow, Felix , Trinka, Eugen , Hocker, Sara, Gaspard, Nicolas , Loddenkemper, Tobias , Trinka, Eugen , Specchio, Nicola , Gofton, Teneille , Abend, Nicholas S. , Hahn, Cecil D. , Navarro, Vincent , Hirsch, Lawrence J

Mayo Clinic

Epilepsia | February 5, 2018 | Volume: 59 | Issue: 4 | Pages: 739-744

10.1111/epi.14016 | PMID 29399791 Get It

SummaryWe convened an international group of experts to standardize definitions of New‐Onset Refractory Status Epilepticus (NORSE), Febrile Infection‐Related Epilepsy Syndrome (FIRES), and related conditions. This was done to enable improved communication for investigators, physicians, families, patients, and other caregivers. Consensus definitions were achieved via email messages, phone calls, an in‐person consensus conference, and collaborative manuscript preparation. Panel members were from 8 countries and included adult and pediatric experts in epilepsy, electroencephalography (EEG), and neurocritical care. The proposed consensus definitions are as follows: NORSE isa clinical presentation, not a specific diagnosis, in a patient without active epilepsy or other preexisting relevant neurological disorder, with new onset of refractory status epilepticus without a clear acute or active structural, toxic or metabolic cause. FIRES is a subcategory of NORSE, applicable for all ages, that requires a prior febrile infection starting between 2 weeks and 24 hours prior to onset of refractory status epilepticus, with or without fever at onset of status epilepticus. Proposed consensus definitions are also provided for Infantile Hemiconvulsion‐Hemiplegia and Epilepsy syndrome (IHHE) and for prolonged, refractory and super‐refractory status epilepticus. This document has been endorsed by the Critical Care EEG Monitoring Research Consortium. We hope these consensus definitions will promote improved communication, permit multicenter research, and ultimately improve understanding and treatment of these conditions.
Fibrin glue mediated delivery of bone anabolic reagents to enhance healing of tendon to bone
Søreide, Endre , Denbeigh, Janet M. , Lewallen, Eric A. , Samsonraj, Rebekah M. , Berglund, Lawrence J., Dudakovic, Amel , Cool, Simon M. , Nordsletten, Lars , Wijnen, André J. van , van Wijnen, Andre J , Kakar, Sanjeev

Mayo Clinic

Journal of Cellular Biochemistry | February 1, 2018 | Volume: 119 | Issue: 7 | Pages: 5715-5724

10.1002/jcb.26755 | PMID 29388702 Get It

AbstractTendon graft healing in bone tunnels for the fixation of intra‐articular ligament reconstructions may limit clinical outcome by delaying healing. This study assesses the effects of hydrogel‐mediated delivery of bone anabolic growth factors in a validated model of tendon‐to‐bone tunnel healing. Forty‐five Wistar rats were randomly allocated into three groups (BMP2‐treated, GSK126‐treated, and placebo). All animals underwent a tendon‐to‐bone tunnel reconstruction. Healing was evaluated at 4 weeks by biomechanical assessment, micro‐computed tomography (bone mineral density, bone volume, cross sectional area of bone tunnels), and traditional histology. Adverse events associated with the hydrogel‐mediated delivery of drugs were not observed. Results of our biomechanical assessment demonstrated favorable trends in animals treated with bone anabolic factors for energy absorption (P = 0.116) and elongation (P = 0.054), while results for force to failure (P = 0.691) and stiffness (P = 0.404) did not show discernible differences. Cross sectional areas for BMP2‐treated animals were reduced, but neither BMP2 nor GSK126 administration altered bone mineral density (P = 0.492) or bone volume in the bone tunnel. These results suggest a novel and positive effect of bone anabolic factors on tendon‐to‐bone tunnel healing. Histological evaluation confirmed absence of collagen fibers crossing the soft tissue‐bone interface indicating immature graft integration as expected at this time point. Our study indicates that hydrogel‐mediated delivery of BMP2 and GSK126 appears to be safe and has the potential to enhance tendon‐to‐bone tunnel healing in ligament reconstructions.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Guchelaar, Henk‐Jan , Schwab, Matthias , Province, Michael A. , Symmans, W. Fraser , McLeod, Howard L. , Ratain, Mark J. , Zembutsu, Hitoshi , Schaik, Ron HN van , Caudle, Kelly E. , Ingle, James N. , Symmans, W Fraser , Goetz, Matthew P. , Sangkuhl, Katrin , Whirl‐Carrillo, Michelle , Gaedigk, Andrea , Klein, Teri E. , Schwab, Matthias , Province, Mike

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 31, 2018 | Volume: 103 | Issue: 5 | Pages: 770-777

10.1002/cpt.1007 | PMID 29385237 Get It

Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dingli, David , Cornell, Robert F. , Huff, Carol Ann , Bhutani, Divaya , Zonder, Jeffrey A. , Cole, Craig E. , Vij, Ravi , Abonour, Rafat , Schiller, Gary J. , Parker, Terri L., Costa, Luciano J. , Kaminetzky, David , Hoffman, James E. , Chari, Ajai , Wier, Scott Van, Ahmann, Gregory , Lopez, Ilsel, Kauffman, Michael , Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla, Choe-Juliak, Cassandra, Stewart, A. Keith, Vogl, Dan T. , Cornell, Robert Frank, Zonder, Jeffrey, Nooka, Ajay, Richter, Joshua , Cole, Craig, Schiller, Gary, Yee, Andrew J. , Van Wier, Scott, Picklesimer, Carla D, Chari, Ajai , Dingli, David , Bhutani, Divaya , Costa, Luciano J , Jagannath, Sundar , Baz, Rachid , Nooka, Ajay K. , Jakubowiak, Andrzej , Yee, Andrew J , Siegel, David S. , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | January 30, 2018 | Volume: 36 | Issue: 9 | Pages: 859-866

10.1200/jco.2017.75.5207 | PMID 29381435 Get It

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.
Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease
Ouyang, Bichun , Verhagen, Leo, Shill, Holly A. , Adler, Charles H. , Beach, Thomas G. , Kordower, Jeffrey H. , AZSAND, the, Adler, C H , Pal, Gian D. , Serrano, Geidy E. , AZSAND, the

Mayo Clinic

Movement Disorders | January 30, 2018 | Volume: 33 | Issue: 4 | Pages: 652-654

10.1002/mds.27280 | PMID 29380902 Get It

Present developments in reaching an international consensus for a model-based approach to particle beam therapy
Prayongrat, Anussara , Umegaki, Kikuo, Schaaf, A. van der , Whitaker, Thomas J. , McNutt, Todd , Matsufuji, Naruhiro, Mizuta, Masahiko, Ogawa, Kazuhiko , Date, Hiroyuki, Moriwaki, Kensuke , Ito, Yoichi M. , Kobashi, Keiji , Dekura, Yasuhiro , Shirato, Hiroki , Whitaker, Thomas, Koong, Albert C , Lin, Steven H. , Graves, Edward Elliot , Shimizu, Shinichi

Mayo Clinic

Journal of Radiation Research | January 26, 2018 | Volume: 59 | Issue: suppl_1 | Pages: i72-i76

10.1093/jrr/rry008 | PMID 29529229 Get It

Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes
Sfeir, Maroun M. , Borczuk, Alain , Soave, Rosemary, Jenkins, Stephen G., Walsh, Thomas J. , Small, Catherine B. , Schuetz, Audrey, Schuetz, Audrey N. , Besien, Koen van

Mayo Clinic

Journal of Clinical Pathology | January 24, 2018 | Volume: 71 | Issue: 7 | Pages: 626-630

10.1136/jclinpath-2017-204777 | PMID 29367301 Get It

Introduction Mycobacterial spindle cell pseudotumour (MSP) is a rare disease characterised by tumour-like local proliferation of spindle-shaped histiocytes containing acid-fast positive mycobacteria. The aim of this literature review is to describe the clinical parameters and treatment outcomes of patients with MSP. Methods A literature search was conducted using the search terms related to mycobacteria and spindle cell tumours. A previously unreported stem cell transplant recipient from our institution diagnosed with MSP was also included. Demographics, comorbidities, site of infection, treatment and clinical outcomes were analysed. Results Fifty-one patients were analysed. Twenty-six (51%) had HIV infection. Mycobacterium avium complex was the most frequent organism isolated in 24 (47.1%) followed by Mycobacterium tuberculosis complex in eight (16%) cases. Lymph nodes were the most common site of infection (45.1%). Twenty (39.2%) patients received antimycobacterial agents, 12 (23.5%) underwent surgical resection and six (11.8%) received antimycobacterial agents plus surgery. Treatment was successful in 24 (47.1%) patients and failed in 15 (29.4%); 13 of these 15 patients died. Antimycobacterial therapy was significantly associated with successful outcome compared with surgical resection or no treatment (P<0.001). Conclusion MSP is a rare condition associated primarily with immunodeficiencies. Antimycobacterial therapy is significantly associated with successful outcome.
Single-site ventricular pacing via the coronary sinus in patients with tricuspid valve disease
Noheria, Amit , Zyl, Martin van , Scott, Luis R. , Madhavan, Malini , Asirvatham, Samuel J. , Van Zyl, Martin, Asirvatham, Samuel J , Srivathsan, Komandoor , McLeod, Christopher J.

Mayo Clinic

EP Europace | January 24, 2018 | Volume: 20 | Issue: 4 | Pages: 636-642

10.1093/europace/euw422 | PMID 28339945 Get It

Utility of Pathology Imagebase for standardisation of prostate cancer grading
Egevad, Lars , Delahunt, Brett , Bostwick, David G., Cheville, John C. , Evans, Andrew , Fine, Samson W. , Grignon, David J. , Humphrey, Peter A. , Hörnblad, Jonas, Iczkowski, Kenneth A. , Kench, James G. , Leite, Kátia Ramos Moreira , McKenney, Jesse K. , Pan, Chin‐Chen , Samaratunga, Hemamali , Srigley, John R., Takahashi, Hiroyuki , True, Lawrence D. , Tsuzuki, Toyonori , Varma, Murali , Zhou, Ming , Clements, Mark , McKenney, Jesse K , Pan, Chin-Chen , Tsuzuki, Toyonori , Samaratunga, Hemamali , Berney, Daniel M. , Compérat, Éva , Kristiansen, Glen , Magi‐Galluzzi, Cristina , OXLEY, JON D. , Kwast, Theodorus van der

Mayo Clinic

Histopathology | January 23, 2018 | Volume: 73 | Issue: 1 | Pages: 8-18

10.1111/his.13471 | PMID 29359484 Get It

AimsDespite efforts to standardise grading of prostate cancer, even among experts there is still a considerable variation in grading practices. In this study we describe the use of Pathology Imagebase, a novel reference image library, for setting an international standard in prostate cancer grading.Methods and resultsThe International Society of Urological Pathology (ISUP) recently launched a reference image database supervised by experts. A panel of 24 international experts in prostate pathology reviewed independently microphotographs of 90 cases of prostate needle biopsies with cancer. A linear weighted kappa of 0.67 (95% confidence interval = 0.62–0.72) and consensus was reached in 50 cases. The interobserver weighted kappa varied from 0.48 to 0.89. The highest level of agreement was seen for Gleason score (GS) 3 + 3 = 6 (ISUP grade 1), while higher grades and particularly GS 4 + 3 = 7 (ISUP grade 3) showed considerable disagreement. Once a two‐thirds majority was reached, images were moved automatically into a public database available for all ISUP members at www.isupweb.org. Non‐members are able to access a limited number of cases.ConclusionsIt is anticipated that the database will assist pathologists to calibrate their grading and, hence, decrease interobserver variability. It will also help to identify instances where definitions of grades need to be clarified.